Low-dose ketamine to improve consistency of anesthetic depth

Effect of Subanaesthetic Dose of Ketamine on Depth of Anaesthesia Consistency During Propofol Total Intravenous Anaesthesia Administered by Closed-loop Anaesthesia Delivery System in Adults Undergoing Elective Laparoscopic Surgery: a Randomised Controlled Study

Not applicable Interventional Sir Ganga Ram Hospital · NCT06986109

This study will test whether adding a small dose of ketamine to propofol makes the depth of general anesthesia more consistent for adults having elective laparoscopic surgery.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment106 (estimated)
Ages18 Years to 65 Years
SexAll
SponsorSir Ganga Ram Hospital Academic / other
Locations1 site (New Delhi, National Capital Territory of Delhi)
Trial IDNCT06986109 on ClinicalTrials.gov

What this trial studies

Adults scheduled for elective laparoscopic surgery lasting more than 60 minutes receive propofol total intravenous anesthesia (TIVA) combined with either a subanesthetic dose of ketamine or a placebo while clinical parameters are recorded. Depth of anesthesia will be monitored using the Bispectral Index (BIS) and a closed-loop anesthesia delivery system to measure variability and consistency of sedation. The trial excludes patients with significant cardiovascular, hepatic, renal, psychiatric, endocrine disorders, recent sedative use, substance abuse, or anticipated postoperative ventilation. Outcomes compare BIS variability and stability between the ketamine and placebo groups to see if ketamine reduces fluctuations in anesthetic depth.

Who should consider this trial

Good fit: Adults (ASA I–II) scheduled for elective laparoscopic surgery expected to last over 60 minutes and without major organ dysfunction or psychiatric disease.

Not a fit: Patients with uncontrolled cardiovascular, liver, kidney, endocrine, or psychiatric disease, recent sedative or antipsychotic use, substance abuse, or those who need postoperative ventilation are excluded and unlikely to benefit.

Why it matters

Potential benefit: If successful, adding low-dose ketamine could produce more stable anesthetic depth, potentially reducing episodes of under- or over-sedation and improving patient safety and recovery.

How similar studies have performed: Previous work has shown ketamine can alter EEG patterns and provide analgesic benefits as an adjuvant to propofol, but its specific effect on BIS consistency within closed-loop TIVA systems is not well established.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* ASA physical status I and II.
* Patients scheduled for elective laparoscopic surgery with estimated duration greater than 60-minutes.

Exclusion Criteria:

* Known uncontrolled cardiovascular disease (e.g., hypertension, systolic and diastolic dysfunction)
* Liver function abnormality (liver enzymes \>2 times the normal range)
* Kidney function abnormality (serum creatinine \>1.4 mg/dl)
* Known psychiatric or neurological disorder
* Known uncontrolled endocrine disorder (diabetes mellitus, hypothyroidism)
* Known allergy or hypersensitivity to the study drug
* Recent intake of sedative medication or anti-psychotic medication
* Substance abuse
* Anticipated need for postoperative ventilation
* Refusal to informed consent

Where this trial is running

New Delhi, National Capital Territory of Delhi

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions AnesthesiaketaminepropofolBi-spectral indexclosed-loop anaesthesia delivery system
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.